Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Node Pharmaceuticals, has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of Olmesartan Medoxomil and Hydrochlorothiazide tablets, which are primarily used for the treatment of hypertension [1] Company Summary - Tianyu Co., Ltd. is expanding its product portfolio in the pharmaceutical sector with the FDA approval of a new generic drug [1] - The approved drug is aimed at addressing the hypertension market, which is significant given the prevalence of high blood pressure in the population [1] Industry Summary - The approval of generic drugs like Olmesartan Medoxomil and Hydrochlorothiazide is indicative of the ongoing growth and competitiveness in the pharmaceutical industry, particularly in the hypertension treatment segment [1] - The FDA's approval process for generic drugs is crucial for increasing access to affordable medications in the healthcare market [1]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Node Pharmaceuticals, has received approval from the U.S. FDA for the abbreviated new drug application (ANDA) of Olmesartan Medoxomil and Hydrochlorothiazide tablets, marking a significant milestone for the company in entering the U.S. market [1] Group 1 - The approved drug is primarily used for the treatment of hypertension and was developed by Cosette Pharmaceuticals, Inc., which launched it in the U.S. in June 2003 [1] - Node Pharmaceuticals submitted the ANDA to the U.S. FDA in February 2020, with a total R&D investment of approximately 7.6277 million yuan to date [1] - This approval represents the first time the company's formulation products have received U.S. FDA approval, indicating a deepening of the company's overseas business layout [1]

Core Viewpoint - Yuheng Pharmaceutical has demonstrated outstanding performance in a relatively sluggish pharmaceutical industry, achieving significant growth in core products and cost reduction efforts, with a notable increase in net profit and cash flow in 2024 and Q1 2025 [1][2][7] Financial Performance - In 2024, the company's net profit attributable to shareholders increased by 93.43% year-on-year, reaching 233 million yuan, while the net profit excluding non-recurring items surged by 243.42% to 183 million yuan [1] - For Q1 2025, the net profit attributable to shareholders and net profit excluding non-recurring items grew by 15.24% and 54.74% year-on-year, amounting to approximately 60.25 million yuan and 49.73 million yuan, respectively [1] - The operating cash flow increased by 49.88% year-on-year to 411 million yuan, and the weighted average return on equity rose to 12.89%, up 5.63 percentage points [2] - The basic earnings per share increased by 93.60% to 0.1059 yuan/share in 2024, with a further 16.60% growth in Q1 2025, reaching 0.0274 yuan/share [2] Asset Quality Improvement - By the end of 2024, the net assets attributable to shareholders grew by 17.39% year-on-year to approximately 1.951 billion yuan, while the debt-to-asset ratio decreased by 15.58 percentage points to 30.17%, the lowest level in a decade [2] - The company’s operational efficiency improved, with current asset turnover increasing from 1.77 times to 2.40 times, and total asset turnover rising from 0.73 times to 0.82 times [3] Sales Efficiency and Cost Management - In 2024, the company enhanced sales efficiency through organizational adjustments and process management, resulting in a 25.82% decrease in sales expenses, with the sales expense ratio falling to 32.48% [3] - Management expenses and financial costs also saw significant reductions, with management expenses down 18.29% and financial expenses down 103.41% in 2024 [3] Product Development and Innovation - The company has maintained a "Product First" strategy, expanding its product line from orthopedics to major therapeutic areas such as cardiovascular and cerebrovascular diseases, with several core products experiencing rapid sales growth [4] - In 2024, sales of the exclusive traditional Chinese medicine product An Nao Wan/Pian grew over 90%, while the injection of multiple vitamins maintained an 80% market share with a 40% sales increase [4] - The company has a robust pipeline of over 20 projects, with several products receiving drug approval numbers and others undergoing consistency evaluations [6] Strategic Partnerships - Yuheng Pharmaceutical has strengthened its collaboration with the global pharmaceutical company Daiichi Sankyo, signing promotional agreements for new products, which are expected to contribute positively to the company's performance [5][6] Market Confidence and Shareholder Engagement - The company launched an equity incentive plan covering over 100 key personnel and implemented a share repurchase plan, reflecting confidence in its future development [6] - Major shareholders have collectively increased their holdings by nearly 30 million shares, indicating strong market confidence in the company's long-term value proposition [6][7]